Xpert® TV
Fast molecular detection of Trichomonas vaginalis for both women and men.
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXTV-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
product image
ASWAB Dual Swab Specimen Collection Kit (Pack of 50)
SWAB/A-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
product image
Swab Specimen Collection Kit (Pack of 50)
SWAB/G-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
product image
Urine Collection Kit (Pack of 50)
URINE/A-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

Trichomoniasis, chlamydia, and gonorrhea are the three most prevalent, treatable STDs in the U.S. If left untreated, complications can include infertility, pelvic inflammatory disease, pregnancy complications, and increased risk of HIV acquisition.1

CDC recommends:1
  • Annual CT/NG screening of all sexually active women under 25
  • Screening of other at-risk individuals including MSM*
  • Testing for chlamydia, gonorrhea, & trichomoniasis using NAATs^ (PCR)
  • Timely testing to support prompt treatment decisions
(1) Centers for Disease Control and Prevention. Trichomoniasis —CDC Fact Sheet. Accessed Aug 2021. https://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm
(2) Van Gerwen O, et al. Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. Clin Infect Dis. 2021 Jun 3; ciab514.
(3) Workowski KA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70 (No. RR-4):1–187.
* Early Assay Termination for positive results.

The Solution

Accurate on-demand PCR results are ready when you need them
  • On‑demand results can support clinical workflows by providing results during the patient visit
  • The test supports the use of patient‑collected vaginal swab specimens in clinical settings
  • The assay supports multiple validated specimen types

The Impact

Provide fast patient results to:
  • Enable test results during the patient visit
  • Support efficient patient care workflows
  • Support timely identification of infection to inform clinical management.
  • Help inform appropriate clinical decision‑making regarding antibiotic use

Frequently Asked Questions

Xpert TV is a qualitative in vitro diagnostic test for the detection of Trichomonas vaginalis genomic DNA. The test utilizes automated real-time PCR to amplify and detect Trichomonas vaginalis genomic DNA. (1)

The Xpert TV test uses female and male urine specimens, endocervical swab specimens, or patient-collected vaginal swab specimens (collected in a clinical setting). The Xpert TV test is intended to aid in the diagnosis of trichomoniasis (TV) in symptomatic or asymptomatic individuals. (1)

The protozoan Trichomonas vaginalis is responsible for trichomoniasis, which is a common sexually transmitted infection that can infect both men and women. There are 7.4 million cases of trichomoniasis annually in the United States. Trichomoniasis can be symptomatic or asymptomatic. (1)

In women, trichomoniasis is one of a range of conditions that may include vaginal discharge. Symptoms in females can include itching, burning, redness, or soreness of the genitals, unusual odor, discomfort with urination, or a thin clear, white, yellow, or green discharge. (2) In men, trichomoniasis may cause non-gonococcal urethritis (NGU). Symptoms in males can include itching or burning inside the penis, burning after ejaculation or urination, or penile discharge. (1)

For women, consider screening those receiving care in high-prevalence settings (e.g., STI clinics and correctional facilities) and for asymptomatic women at high risk for infection (e.g., women with multiple sex partners, transactional sex, drug misuse, or a history of STI or incarceration).  For persons with HIV, screening is recommended for sexually active women at entry to care and at least annually thereafter. (2)

References:

  1. Cepheid. Xpert TV Package Insert. Accessed Dec. 18, 2023. https://www.cepheid.com/en-CYntent/dam/www-cepheid-com/documents/package-insert-files/Xpert-TV-ENGLISH-Package-Insert-301-2887-Rev.%20D.pdf
  2. CDC. Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. June 6, 2022. Accessed Dec. 18, 2023. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm